World Health Organization Western Research Articles

Multidrug-Resistant Neisseria Gonorrhoeae Infection

Gonorrhea, an important Sexually Transmitted Infection (STI), continues to pose a significant public health challenge. According to estimations by the World Health Organization (WHO), there were approximately 82.4 million new cases of this infection among adolescents and adults aged 15-49 years in 2020, with a global incidence rate ranging from 11-29 per 1000 women and 10-43 per 1000 men [1,2]. Most cases were reported in the WHO African and Western Pacific regions. This data underscores the necessity for increased efforts to address the problem of gonorrhea on a global scale [3].

Global analysis on the mutations associated with multidrug-resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta-analysis

BackgroundThe emergence of multidrug-resistant (MDR) strains of genital pathogens, notably Mycoplasma genitalium and Ureaplasma spp., constitutes a significant global threat today. The present study aimed to evaluate the prevalence and trend of changes in MDR mycoplasma and ureaplasma strains.MethodsAn exhaustive search was performed across the ISI Web of Science, PubMed, Scopus, ScienceDirect, and Google Scholar databases to accumulate relevant studies without restrictions until April 2023. We used event rate and corresponding 95% confidence intervals to determine the frequency of resistance-related mutations and examine the trend of antibiotic resistance changes.ResultsThe data from 27 studies, including 24,662 patients across 14 countries, were evaluated. Out of the total studies, 20 focused on M. genitalium infections, and five on Ureaplasma spp. The frequency of resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones in clinical strains of M. genitalium was 43.5%, 13.1%, and 18.6%, respectively. The prevalence of M. genitalium strains with double resistance and MDR was 11.0% and 17.4%, respectively. The incidence of both double-drug-resistant and MDR strains was higher in the World Health Organization (WHO) Western Pacific Region than in European and American populations. For Ureaplasma strains, resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones were 40.8%, 25.7%, and 90.3%, respectively. The rate of antibiotic resistance was higher in the African population compared to the European and WHO Western Pacific Regions. The rate of MDR Ureaplasma infections was 13.2%, with a higher incidence in the African population compared to the WHO Western Pacific and European regions.ConclusionThe proliferation and spread of MDR Mycoplasma and Ureaplasma strains present a significant public health challenge. The situation is indeed alarming, and the rising trend of MDR M. genitalium and MDR Ureaplasma infections suggests that therapies involving macrolides and fluoroquinolones may become less effective.

WHO International Standard Terminologies on Traditional Chinese Medicine: Use in Context, Creatively

WHO International Standard Terminologies on Traditional Chinese Medicine: Use in Context, Creatively

Health and economic benefits of meeting WHO air quality guidelines, Western Pacific Region.

To quantify the number of avoidable annual deaths and associated economic benefits from meeting the World Health Organization (WHO) air quality guidelines for ambient concentrations for fine particulate matter (PM2.5) for Member States of the WHO Western Pacific Region. Using the AirQ+ software, we performed a quantitative health impact assessment comparing country-level PM2.5 concentrations with the 2005 and 2021 air quality guidelines recommended maximum concentrations of 10 and 5μg/m3, respectively. We obtained PM2.5 data from the WHO Global Health Observatory (latest available year 2016), and population and mortality estimates from the United Nations World Population Prospects database for the latest 5-year period available (2015-2019), which we averaged to 1-year estimates. A risk estimate for all-cause mortality, based on a meta-analysis, was embedded within AirQ+ software. Our economic assessment used World Bank value of a statistical life adjusted to country-specific gross domestic product (latest available year 2014). Data were complete for 21 of 27 Member States. If these countries achieved the 2021 guidelines for PM2.5, an estimated 3.1 million deaths would be avoided annually, which are 0.4 million more deaths avoided than meeting the 2005 guidelines. China would avoid the most deaths per 100 000 population (303 deaths) and Brunei Darussalam the least (5 deaths). The annual economic benefit per capita ranged from 5781 United States dollars (US$) in Singapore to US$143 in Solomon Islands. Implementing effective measures to reduce PM2.5 emissions would save a substantial number of lives and money across the Region.

Epidemiology of dengue reported in the World Health Organization's Western Pacific Region, 2013-2019.

The global burden of dengue, an emerging and re-emerging mosquito-borne disease, increased during the 20-year period ending in 2019, with approximately 70% of cases estimated to have been in Asia. This report describes the epidemiology of dengue in the World Health Organization's Western Pacific Region during 2013-2019 using regional surveillance data reported from indicator-based surveillance systems from countries and areas in the Region, supplemented by publicly available dengue outbreak situation reports. The total reported annual number of dengue cases in the Region increased from 430 023 in 2013 to 1 050 285 in 2019, surpassing 1 million cases for the first time in 2019. The reported case-fatality ratio ranged from 0.19% (724/376 972 in 2014 and 2030/1 050 285 in 2019) to 0.30% (1380/458 843 in 2016). The introduction or reintroduction of serotypes to specific areas caused several outbreaks and rare occurrences of local transmission in places where dengue was not previously reported. This report reinforces the increased importance of dengue surveillance systems in monitoring dengue across the Region.

Defining Preterm Birth and Stillbirth in the Western Pacific: A Systematic Review.

Preterm birth and stillbirth are important global perinatal health indicators. Definitions of these indicators can differ between countries, affecting comparability of preterm birth and stillbirth rates across countries. This study aimed to document national-level adherence to World Health Organization (WHO) definitions of preterm birth and stillbirth in the WHO Western Pacific region. A systematic search of government health websites and 4 electronic databases was conducted. Any official report or published study describing the national definition of preterm birth or stillbirth published between 2000 and 2020 was eligible for inclusion. A total of 58 data sources from 21 countries were identified. There was considerable variation in how preterm birth and stillbirth was defined across the region. The most frequently used lower gestational age threshold for viability of preterm birth was 28 weeks gestation (range 20-28 weeks), and stillbirth was most frequently classified from 20 weeks gestation (range 12-28 weeks). High-income countries more frequently used earlier gestational ages for preterm birth and stillbirth compared with low- to middle-income countries. The findings highlight the importance of clear, standardized, internationally comparable definitions for perinatal indicators. Further research is needed to determine the impact on regional preterm birth and stillbirth rates.

Mapping timely access to emergency and essential surgical services: The Malaysian experience.

Surgical conditions form a significant proportion of the global burden of disease. Since the 2015 World Health Assembly resolution A68.15, there is recognition that the provision of essential surgical care is an integral part of universal access to health care. The Lancet Commission on Global Surgery proposed its first surgical indicator to measure a population's access to the Bellwether procedures (laparotomy, caesarean section and treatment of open fracture) within two hours. Bellwether access is a proxy for emergency and essential surgical care. This project aims to map essential surgical access to the Bellwether procedures in Malaysia. The location and capability of hospitals to perform the Bellwether procedures was obtained from the Ministry of Health (MoH) and MoH hospital specific websites. The Malaysian population data were retrieved from the national department of statistics. Times for patients to travel to hospital were calculated by combining manual contouring and geospatial mapping. There were 49 Bellwether-capable MoH hospitals serving a national population of 32.5 million. Overall 94% of Malaysia's population have access to the Bellwethers within two hours. This coverage is universal in West (Peninsular) Malaysia, but there is only 73% coverage in East Malaysia, with 1.8 million residents of Sabah and Sarawak not having timely access. Malaysia's Bellwether capacity compares well with other countries in World Health Organisation's Western Pacific region. There is good access to essential and emergency surgical services in Malaysia. The incomplete access for 1.8 million people in East Malaysia will inform national surgical planning.

A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01).

Background and Aims: The World Health Organization (WHO) Western Pacific Region set a target of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030. To assess the feasibility of this target in China, we carried out an epidemiological study to investigate the status quo of MTCT in the real-world setting.Methods: One thousand and eight hepatitis B surface antigen-positive pregnant women were enrolled at 10 hospitals. Immunoprophylaxis was administered to infants. In addition, mothers with HBV DNA level >2,000,000 IU/mL were advised to initiate antiviral therapy during late pregnancy. A health application called SHIELD was used to manage the study.Results: Nine hundred and five of the enrolled mothers, with 924 infants, completed the follow-up. Birth-dose hepatitis B vaccine and hepatitis B immunoglobulin were received by 99.7% and 99.7% of infants, respectively, within 24 h after birth. There were 446 mothers who received antiviral therapy, including 72.3% of the mothers with HBV DNA level >2,000,000 IU/mL and 21.0% of the mothers with HBV DNA level <2,000,000 IU/mL. Eight infants were infected with HBV. The overall rate of MTCT was 0.9%. Birth defects were rare (0.5% among infants with maternal antiviral exposure versus 0.7% among infants without exposure; p=1.00).Conclusions:The MTCT rate was lower than the WHO Western Pacific Region elimination MTCT target in this real-world study, indicating that a comprehensive management composed of immunoprophylaxis to infants and antiviral prophylaxis to mothers may be a feasible strategy to achieve the 2030 WHO elimination goal.

Hepatitis B vaccination and immunotherapies: an update.

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%) and in the WHO African Region (6.1%). The HBV vaccine is the best protection against chronic HBV infection and its complications. Globally, routine infant immunization against HBV has increased with an estimated coverage of 84% in 2017. Nevertheless, in many countries further efforts are needed to implement this coverage and ensure national immunization programs for people at major risk for HBV infection. Therapeutic vaccination in chronic HBV infected patients can cause anti-HBV immune responses able to remove and/or cure infected hepatocytes. It shows promising results in murine model and human trials, but these results need to be consolidated by further multicenter clinical studies. In particular, the efficacy of therapeutic vaccine seems to improve by combination therapies.

A Multi-Perspective Review on Dengue Research.

Dengue fever is a disease which is caused by a family of viruses named Flaviviridae which are transmitted by female Aedes mosquitoes. Today, this is endemic in more than 100 nations in the World Health Organization's African, Americas, Eastern Mediterranean, South-East Asia and Western Pacific locales. The treatment of typical dengue is focused on relieving the symptoms and signs. Carica papaya is a very common plant whose leaf extract is used in the treatment of this disease. Despite extensive research on Dengue, not a single vaccine or anti-viral drug was available until 2016 (a partially effective Chimeric Yellow fever virus treated by DENV-Tetravalent Dengue Vaccine for dengue fever made by Sanofi Pasteur). This review highlights dengue fever's current situation and explains the importance of Natural chemical moieties like methionine-proline anilides, tetrapeptide aldehyde uncovered via Structure Activity Relationship studies. Also, we have reviewed the drug candidates currently in the clinical trials that have the potential to solve these issues. Important patents in the past 20 years have been outlined in this review. An in depth Protein Data Bank analysis of the different possible target proteins that can potentially have a major role in curing Dengue fever has been conducted.

Appropriate BMI Criteria for Indian Population: Does It Help Stratify Obstructive Sleep Apnea (OSA) Patients Better?

Obstructive sleep apnea (OSA) is a common yet unrecognized medical problem with significant morbidity. It is commonly considered an obesity-related problem, although not uncommon in non-obese patients of Indian origin. Currently, the World Health Organization (WHO) Western BMI criteria are widely used to classify obesity levels. Indian population has a different association between body mass index (BMI), percentage of body fat, and health risks compared to the western population. Due to these ethnic variations, applying the appropriate criteria—the WHO recommendation for appropriate BMI for Asian population—would be more suitable for identifying obesity in Indians, and, hence, to identify those at risk for OSA. We aimed to explore the discrepancy that could arise by applying the WHO Western BMI criteria to the Indian population which might misclassify and exclude those who are at risk for obesity-related OSA. This is a retrospective study of patients who presented to Nithra Institute of sleep sciences, Chennai, India, from May 2015 to May 2017. Patients who underwent polysomnography and diagnosed with OSA were included. Data pertaining to demographics, BMI, and severity of OSA were collected and analyzed. Patients were classified into different weight bands based on both the Western and Asian BMI criteria and compared. Stratification based on severity of OSA and its association with both the BMI classification was also analyzed. During the study period, 904 patients were clinically suspected to have OSA, of whom 787 patients underwent polysomnography. Of these, 754 patients were confirmed to have OSA and were included in the study. [626 males (83%)/128 females (16.9%); mean age—50.7 ± 28.6 years]. 735 (97.5%) patients were classified as overweight/obese as per Asian BMI, whereas only 695 (92.2%) patients were classified as overweight/obese as per Western BMI classification. With respect to the association of the BMI categories with the severity of OSA, there were significant differences between the numbers of severe OSA patients in each weight band of Asian BMI when compared to Western BMI. OSA may be underestimated clinically in Indian population when Western BMI criteria is applied. Asian BMI as recommended by WHO is more suitable in reflecting the correlation between obesity and OSA than the western BMI criteria.

PanStop: a decade of rapid containment exercises for pandemic preparedness in the WHO Western Pacific Region.

Member States in the Western Pacific Region (WPR) of the World Health Organization (WHO), are highly vulnerable to emerging influenza viruses that have the potential to cause global pandemics. A well-coordinated strategy for preparedness is required at national and international levels for a robust response and to mitigate the potentially dire consequences of the next influenza pandemic. Of 37 countries and areas in the region, 23 have publically available national pandemic influenza preparedness and response plans; of these, only 17% have been updated in the last five years. However, many plans are pending update and may benefit from integrating some components of the 2017 WHO pandemic influenza risk management guide. Additionally, many plans need to be operationalized to test their functionality. Since 2007, WPRO has conducted annual PanStop exercises to test pandemic containment plans and RC mechanisms in a simulated environment that imitates pandemic events as they unfold. PanStop exercises provide an opportunity for countries to validate policies, protocols and procedures involved in implementing rapid containment (RC) operations, and to identify strengths and opportunities for improvement in planning activities for pandemic influenza. By participating in exercises such as PanStop and the annual regional International Health Regulation (IHR) Crystal Exercise, and subsequently adapting national preparedness plans based on exercise outcomes, WPR continues to improve readiness for the next influenza pandemic.

Implementing the End TB Strategy in the Western Pacific Region: Translating vision into reality.

The End TB Strategy aims to end the global tuberculosis (TB) epidemic by 2035 in line with the sustainable development goals targets and has been implemented in the World Health Organization (WHO) Western Pacific Region since 2015. Significant progress has been made in implementing this strategy. However, several challenges still remain. In 2016, an estimated 1.8 million people developed TB in the region, and of these about 20% were missed by national TB programmes. The gap in diagnosis and enrolment as well as treatment completion is greater with drug-resistant TB. Many TB-affected families face catastrophic costs due to the disease. Sustaining financing for TB care is a long-term challenge in many countries. This article emphasizes targeted interventions in high-risk populations, including systematic screening and patient-centred TB care. Several other approaches including improving TB diagnostic tools and algorithm, and engaging all care providers are suggested to find missing TB patients. Drug-resistant TB requires additional resourcing for laboratories, enrolment and patient support. Specific measures are required at different levels to mitigate financial burden due to TB including linking TB to overall social protection schemes. The Moscow Ministerial conference in 2017 and upcoming United Nations (UN) 2018 high-level meeting provide an opportunity to raise TB higher on the global agenda, forge partnerships and move towards universal health coverage.

Appropriate bmi criteria for Indian population: does it help stratify obstructive sleep apnea (OSA) patients better?

Obstructive sleep apnea (OSA) is a common yet unrecognized medical problem with significant morbidity. It is commonly considered an obesity-related problem, although not uncommon in non-obese patients of Indian origin. Currently, the World Health Organization (WHO) Western BMI criteria are widely used to classify obesity levels. Indian population has a different association between body mass index (BMI), percentage of body fat, and health risks compared to the western population. Due to these ethnic variations, applying the appropriate criteria—the WHO recommendation for appropriate BMI for Asian population—would be more suitable for identifying obesity in Indians, and, hence, to identify those at risk for OSA. We aimed to explore the discrepancy that could arise by applying the WHO Western BMI criteria to the Indian population which might misclassify and exclude those who are at risk for obesity-related OSA. This is a retrospective study of patients who presented to Nithra Institute of sleep sciences, Chennai, India, from May 2015 to May 2017. Patients who underwent polysomnography and diagnosed with OSA were included. Data pertaining to demographics, BMI, and severity of OSA were collected and analyzed. Patients were classified into different weight bands based on both the Western and Asian BMI criteria and compared. Stratification based on severity of OSA and its association with both the BMI classification was also analyzed. During the study period, 904 patients were clinically suspected to have OSA, of whom 787 patients underwent polysomnography. Of these, 754 patients were confirmed to have OSA and were included in the study. [626 males (83%)/128 females (16.9%); mean age—50.7 ± 28.6 years]. 735 (97.5%) patients were classified as overweight/obese as per Asian BMI, whereas only 695 (92.2%) patients were classified as overweight/obese as per Western BMI classification. With respect to the association of the BMI categories with the severity of OSA, there were significant differences between the numbers of severe OSA patients in each weight band of Asian BMI when compared to Western BMI. OSA may be underestimated clinically in Indian population when Western BMI criteria is applied. Asian BMI as recommended by WHO is more suitable in reflecting the correlation between obesity and OSA than the western BMI criteria.

Frequency of use of the International Classification of Diseases ICD-10 diagnostic categories for mental and behavioural disorders across world regions.

The study aimed to examine variations in the use of International Classification of Diseases, Tenth Edition (ICD-10) diagnostic categories for mental and behavioural disorders across countries, regions and income levels using data from the online World Psychiatric Association (WPA)-World Health Organization (WHO) Global Survey that examined the attitudes of psychiatrists towards the classification of mental disorders. A survey was sent to 46 psychiatric societies which are members of WPA. A total of 4887 psychiatrists participated in the survey, which asked about their use of classification, their preferred system and the categories that were used most frequently. The majority (70.1%) of participating psychiatrists (out of 4887 psychiatrists) reported using the ICD-10 the most and using at least one diagnostic category once a week. Nine out of 44 diagnostic categories were considerably variable in terms of frequency of use across countries. These were: emotionally unstable personality disorder, borderline type; dissociative (conversion) disorder; somatoform disorders; obsessive-compulsive disorder (OCD); mental and behavioural disorders due to the use of alcohol; adjustment disorder; mental and behavioural disorders due to the use of cannabinoids; dementia in Alzheimer's disease; and acute and transient psychotic disorder. The frequency of use for these nine categories was examined across WHO regions and income levels. The most striking differences across WHO regions were found for five out of these nine categories. For dissociative (conversion) disorder, use was highest for the WHO Eastern Mediterranean Region (EMRO) and non-existent for the WHO African Region. For mental and behavioural disorders due to the use of alcohol, use was lowest for EMRO. For mental and behavioural disorders due to the use of cannabinoids, use was lowest for the WHO European Region and the WHO Western Pacific Region. For OCD and somatoform disorders, use was lowest for EMRO and the WHO Southeast Asian Region. Differences in the frequency of use across income levels were statistically significant for all categories except for mental and behavioural disorders due to the use of alcohol. The most striking variations were found for acute and transient psychotic disorder, which was reported to be more commonly used among psychiatrists from countries with lower income levels. The differences in frequency of use reported in the current study show that cross-cultural variations in psychiatric practice exist. However, whether these differences are due to the variations in prevalence, treatment-seeking behaviour and other factors, such as psychiatrist and patient characteristics as a result of culture, cannot be determined based on the findings of the study. Further research is needed to examine whether these variations are culturally determined and how that would affect the cross-cultural applicability of ICD-10 diagnostic categories.

Vaccine strategies: Optimising outcomes

Successful immunisation programmes generally result from high vaccine effectiveness and adequate uptake of vaccines. In the development of new vaccination strategies, the structure and strength of the local healthcare system is a key consideration. In high income countries, existing infrastructures are usually used, while in less developed countries, the capacity for introducing new vaccines may need to be strengthened, particularly for vaccines administered beyond early childhood, such as the measles or human papillomavirus (HPV) vaccine. Reliable immunisation service funding is another important factor and low income countries often need external supplementary sources of finance. Many regions also obtain support in generating an evidence base for vaccination via initiatives created by organisations including World Health Organization (WHO), the Pan American Health Organization (PAHO), the Agence de Médecine Préventive and the Sabin Vaccine Institute. Strong monitoring and surveillance mechanisms are also required. An example is the efficient and low-cost approaches for measuring the impact of the hepatitis B control initiative and evaluating achievement of goals that have been established in the WHO Western Pacific region. A review of implementation strategies reveals differing degrees of success. For example, in the Americas, PAHO advanced a measles-mumps-rubella vaccine strategy, targeting different population groups in mass, catch-up and follow-up vaccination campaigns. This has had much success but coverage data from some parts of the region suggest that children are still not receiving all appropriate vaccines, highlighting problems with local service infrastructures. Stark differences in coverage levels are also observed among high income countries, as is the case with HPV vaccine implementation in the USA versus the UK and Australia, reflecting differences in delivery settings. Experience and research have shown which vaccine strategies work well and the factors that encourage success, which often include strong support from government and healthcare organisations, as well as tailored, culturally-appropriate local approaches to optimise outcomes.

Response to Ebola Virus Disease Outbreak: Experience in Field Epidemiology in Sierra Leone

The Ebola virus disease (EVD) outbreak that occurred in West Africa in 2014 was the largest ever in the world. In Sierra Leone, the number of cases reported peaked in December 2014 and gradually declined. However, the outbreak was not immediately terminated. To support the response of the World Health Organization (WHO) to EVD, the WHO Western Pacific Regional Office established the Western Pacific Ebola Support Team (WEST) with the aim of eliminating EVD in Port Loko District, where a certain number of new cases were still being reported in March 2015. We were dispatched to join WEST as WHO short term consultants in epidemiology for about six weeks from March to June 2015. Here, we describe our activities in the field as epidemiologists to show how Japan can contribute in the area of epidemiology during infectious disease outbreaks of international concern. The analysis suggested that the surveillance data for all the deaths and suspected EVD cases were underreporting the actual number of EVD cases in Port Loko District. Although contact tracing was conducted, new EVD cases were often found among untraced contacts because of inadequate information from residents or insufficient investigation by the contact tracing team. In addition, incomplete monitoring of the health status of close contacts resulted in secondary transmission of the disease. Data managers established a database by centralizing data from the surveillance and contact tracing teams, laboratories, and healthcare facilities. The number of deaths per week recorded by these data sources was lower than the number of deaths per week that would be expected from the national mortality statistics. The team strengthened surveillance and social mobilization in the regions with wide disparities between the actual and reported numbers of deaths. For the on-the-ground activities, the field coordinator, epidemiologists, and social mobilizers, as well as the logistic and administrative support personnel, were all indispensable in supporting the field investigation of these infectious disease outbreaks of public health concern. A field coordinator, in particular, requires outstanding knowledge, experience and skills to lead team operations in liaison with international and local partners and to build confidence among local residents. The development of these human resources and the maintenance of a response team are required for potential future outbreaks, and this is an important area that Japan could prepare for and then contribute to future outbreaks. This report does not represent an official view of the WHO or our affiliates.

Cancer incidence and mortality attributable to alcohol consumption.

Alcohol consumption is a major cause of disease and death. In a previous study, we reported that in 2002, 3.6% of all cases of cancer and a similar proportion of cancer deaths were attributable to the consumption of alcohol. We aimed to update these figures to 2012 using global estimates of cancer cases and cancer deaths, data on the prevalence of drinkers from the World Health Organization (WHO) global survey on alcohol and health, and relative risks for alcohol-related neoplasms from a recent meta-analysis. Over the 10-year period considered, the total number of alcohol-attributable cancer cases increased to approximately 770,000 worldwide (5.5% of the total number of cancer cases)-540,000 men (7.2%) and 230,000 women (3.5%). Corresponding figures for cancer deaths attributable to alcohol consumption increased to approximately 480,000 (5.8% of the total number of cancer deaths) in both sexes combined-360,000 (7.8%) men and 120,000 (3.3%) women. These proportions were particularly high in the WHO Western Pacific region, the WHO European region and the WHO South-East Asia region. A high burden of cancer mortality and morbidity is attributable to alcohol, and public health measures should be adopted in order to limit excessive alcohol consumption.

First round of external quality assessment of dengue diagnostics in the WHO Western Pacific Region, 2013.

Accurate laboratory testing is a critical component of dengue surveillance and control. The objective of this programme was to assess dengue diagnostic proficiency among national-level public health laboratories in the World Health Organization (WHO) Western Pacific Region. Nineteen national-level public health laboratories performed routine dengue diagnostic assays on a proficiency testing panel consisting of two modules: one containing commercial serum samples spiked with cultured dengue viruses for the detection of nucleic acid and non-structural protein 1 (NS1) (Module A) and one containing human serum samples for the detection of anti-dengue virus antibodies (Module B). A review of logistics arrangements was also conducted. All 16 laboratories testing Module A performed reverse transcriptase polymerase chain reaction (RT-PCR) for both RNA and serotype detection. Of these, 15 had correct results for RNA detection and all 16 correctly serotyped the viruses. All nine laboratories performing NS1 antigen detection obtained the correct results. Sixteen of the 18 laboratories using IgM assays in Module B obtained the correct results as did the 13 laboratories that performed IgG assays. Detection of ongoing/recent dengue virus infection by both molecular (RT-PCR) and serological methods (IgM) was available in 15/19 participating laboratories. This first round of external quality assessment of dengue diagnostics was successfully conducted in national-level public health laboratories in the WHO Western Pacific Region, revealing good proficiency in both molecular and serological testing. Further comprehensive diagnostic testing for dengue virus and other priority pathogens in the Region will be assessed during future rounds.

Drug-resistant tuberculosis in the WHO Western Pacific Region.

To review the latest information about tuberculosis (TB) drug resistance and programmatic management of drug-resistant TB in the Western Pacific Region of the World Health Organization (WHO). We analysed routine data reported by countries to WHO from 2007 to 2013, focusing on data from the following: surveillance and surveys of drug resistance, management of drug-resistant TB and financing related to multidrug-resistant TB (MDR-TB) management. In the Western Pacific Region, 4% (95% confidence interval [CI]: 3-6) of new and 22% (95% CI: 18-26) of previously treated TB cases were estimated to have MDR-TB; this means that in 2013, there were an estimated 71,000 (95% CI: 47,000-94,000) MDR-TB cases among notified pulmonary TB cases in this Region. The coverage of drug susceptibility testing (DST) among new and previously treated TB cases was 3% and 20%, respectively. In 2013, 11,153 cases were notified--16% of the estimated MDR-TB cases. Among the notified cases, 6926 or 62% were enrolled in treatment. Among all enrolled MDR-TB cases, 34% had second-line DST and of these, 13% were resistant to fluoroquinolones (FQ) and/or second-line injectable agents. The 2011 cohort of MDR-TB showed a 52% treatment success. Over the last five years, case notification and enrolment have increased more than five times, but the gap between notification and enrolment widened. The increasing trend in detection and enrolment of MDR-TB cases demonstrates readiness to scale up programmatic management of drug-resistant TB at the country level. However, considerable challenges remain.